NCT07516951RecruitingPhase 2
A Phase IIb, Multicentre, Randomised, Double Blind, Placebo Controlled, Three-arm Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability at Week 24 of 2 Doses of CHF10067 (Zampilimab),in Participants With Idiopathic Pulmonary Fibrosis
Chiesi Farmaceutici S.p.A.4 sites in 2 countries240 target enrollmentStarted: July 8, 2026Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Enrollment
- 240
- Locations
- 4
- Primary Endpoint
- Primary Outcome Measure: Absolute change from baseline in ppFVC (percent predicted forced vital capacity) at Week 24.
Study Overview
Brief Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (IPF).
It is a phase IIb, multicentre, randomised, double-blind, placebo-controlled, three-arm parallel-group study.
A total of 240 participants with IPF (Idiomatic Pulmonary Fibrosis) will be randomised in approximately 150 investigational sites in North and Latin America, Europe, Asia, and Oceania.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) The Investigational Medicinal Product (IMP) is blinded for the participant, investigators, and the sponsor. At the study site an unblinded pharmacist (or designee) will prepare the IMP and an unblinded clinical research associate will check the IMP related documentation Unblinded Sponsor and Clinical Research organization's Study Managers and Clinical Supplies representative will be also assigned.
Eligibility Criteria
- Ages
- 40 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Informed consent: Participant's written informed consent obtained prior to any study-related procedure.
- •Sex and age: Male or female, of any race and ethnicity, aged ≥40 years with a life expectancy of at least 1 year at screening in the opinion of the Investigator.
- •Body weight ≥45 kg.
- •Diagnosis of IPF: Diagnosis as defined by the 2018 and 2022 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society Guidelines for a maximum 8 years before screening. The most recent High-resolution computed tomography (HRCT) ≤6 months prior to screening, reviewed by central reading, should be used to confirm the diagnosis.
- •Lung function: FVC ≥45% of predicted normal value and a ratio of forced expiratory volume in the first second (FEV1)/FVC ≥0.7 at screening.
- •Diffusing capacity of the lung for carbon monoxide (DLCO) corrected for haemoglobin ≥25% of predicted normal at screening.
- •Oxygen saturation measured by pulse oximetry (peripheral capillary oxygen saturation [SpO2]) >90% at rest when the maximum oxygen flow is 4 L/min by standard nasal cannula or the equivalent oxygen delivery via reservoir nasal cannula (≤2 L/min).
Exclusion Criteria
- •Participant with a documented diagnosis of coeliac disease.
- •Low respiratory tract infection: Documented low respiratory tract infection in the last 4 weeks prior to screening or documented acute exacerbation of IPF (defined as acute worsening or development of dyspnoea typically <1 month duration;
- •Lung cancer: Active diagnosis or history of lung cancer.
- •Emphysema: HRCT (refer to inclusion criterion [Diagnosis of IPF]), reviewed by central reading, shows the presence of emphysema ≥20% or that the extent of emphysema is greater than the extent of fibrosis.
- •Organ transplantation: End-stage fibrotic disease expected to require organ transplantation within 6 months from screening.
- •Other medical conditions: Clinically relevant and uncontrolled pulmonary (including any non-IPF pulmonary diagnosis), cardiac, hepatic, gastrointestinal, renal, endocrine, metabolic, neurologic, psychiatric disorders, active or untreated latent tuberculosis/tuberculosis infection that may interfere with the participant's ability to complete this study according to the Investigator's judgement.
- •Any other comorbid non-IPF pulmonary condition that may impact FVC according to the Investigator's judgement. Emphysema is allowed, unless it meets the above exclusion criterion regarding emphysema.
- •Participant currently treated, or been treated with cytotoxic and immunosuppressant/modulator drugs within 48 weeks prior to screening. Systemic (IV, intramuscular, or oral) corticosteroids prednisone- equivalent dose of >10 mg/day used for >10 days.
- •Hypersensitivity: Known intolerance and/or hypersensitivity to any of the excipients contained in the formulation or any other substance used in the study.
- •History of allergic or anaphylactic reaction to human, humanised, chimeric immunoglobulins (Igs), or murine monoclonal antibodies.
Arms & Interventions
Arm A
Experimental
CHF10067 (Test Dose 1)
Intervention: CHF10067 (Drug)
Arm C
Placebo Comparator
Placebo
Intervention: Placebo (Other)
Arm B
Experimental
CHF10067 (Test Dose 2)
Intervention: CHF10067 (Drug)
Outcomes
Primary Outcomes
Primary Outcome Measure: Absolute change from baseline in ppFVC (percent predicted forced vital capacity) at Week 24.
Time Frame: At Week 24
Secondary Outcomes
- Categorical relative change from baseline in ppFVC at Week 24 and at Weeks 6, 12, 18, and 30 (5 dichotomous thresholds: -10%, -5%, 0%, 5%, and 10%)(At Weeks 6, 12, 18, 24 and 30)
- Rate of decline in ppFVC over 24 weeks(Up to 24 weeks)
- Absolute and relative change from baseline in FVC (forced vital capacity) milliliter (mL) at Week 24 and at Weeks 6, 12, 18, and 30(At Weeks 6, 12, 18, 24 and 30)
- Categorical absolute change from baseline in FVC (mL) at Week 24 and at Weeks 6, 12, 18, and 30 (5 dichotomous thresholds: -200 mL, -100 mL, 0 mL, 100 mL, and 200 mL)(At Weeks 6, 12, 18, 24 and 30)
- Rate of decline in FVC (mL) over 24 weeks(Up to 24 Weeks)
- Absolute change from baseline in ppFVC at Weeks 6, 12, 18, and 30(At Weeks 6, 12, 18, and 30)
- Relative change from baseline in ppFVC at Week 24 and at Weeks 6, 12, 18, and 30(At Weeks 6, 12, 18, 24 and 30)
- Categorical absolute change from baseline in ppFVC at Week 24 and at Weeks 6, 12, 18, and 30 (5 dichotomous thresholds: -10%, -5%, 0%, 5%, and 10%)(At Weeks 6, 12, 18, 24 and 30)
- Change from baseline in the Living with Pulmonary Fibrosis (L-PF) questionnaire at Week 12 and at Week 24(At Weeks 12 and 24)
- Change from baseline in specific modules of the L-PF questionnaire (symptoms and impact) and within the symptom modules of specific domains (shortness of breath, cough, and fatigue) at Week 12 and at Week 24(At Weeks 12 and 24)
- CHF10067 concentrations at each visit (Week 0 to Week 21)(From Week 0 up to Week 21)
Investigators
Study Sites (4)
Loading locations...
Similar Trials
Recruiting
Phase 2
Study to Assess Efficacy and Safety of Tozorakimab in Adults with Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsCTRI/2025/08/092776AstraZeneca AB540
Recruiting
Phase 1
A Study to Evaluate ALN-2232 in Participants With ObesityObesityNCT07463846Alnylam Pharmaceuticals156
Recruiting
Phase 2
Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.NCT07638852Fudan University58
Recruiting
Phase 1
Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab ImmunotherapyRectal CancerNCT07561060Fudan University50
Recruiting
Phase 2
Two drug therapy versus three drug therapy in resectable locally advanced oral cavity cancerCTRI/2024/07/071188AIIMS, New Delhi204